Amicus Therapeutics Announces European Commission Approval for Galafold™ (Migalastat) in Patients with Fabry Disease in European Union

Amicus – Launch has Begun in Germany – Broad Label for All Fabry Patients with an Amenable Genetic Mutation First Precision Medicine Approved for Fabry Disease Click here

Read More

Subscribe to Our Newsletter